TickerGuard
Buy Day today: Neutral (59) Mixed market breadth · major macro event coming up
TAK

Takeda Pharmaceutical Co Ltd

Healthcare · Drug Manufacturers - Specialty & Generic

17.40$ -0.1% vs. previous close Closing price · As of: Aug 13, 2026

Statements

Cash Flow

Takeda Pharmaceutical Co Ltd (TAK) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at 127,623 million JPY. Tick rows to compare them in a chart.

All figures in millions of JPY.

Tick rows to compare them in a chart (up to 4)

Cash Flow TAK
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
198,905 146,451 278,588 170,304 280,963 383,756 222,159 215,423 378,228 373,252 74,528 127,623 953,631
182,696 187,061 186,744 192,220 192,452 186,955 189,769 181,636 184,982 190,639 163,870 163,042 702,533
18,535 18,706 18,188 15,386 21,554 18,300 17,627 16,531 18,731 17,802 19,711 18,190 74,434
-4,991
1,590 -166,022 59,376 -80,194 -70,810 88,759 2,873 -33,701 21,938 -39,331 250,999 -158,662 74,944
70,043 77,124 64,326 153,491 92,452 56,651 92,724 75,068 52,825 222,373 64,393 53,811 393,402
-327,109 -75,269 -61,484 -156,693 -75,131 -115,555 -19,681 -33,193 -48,133 -229,798 -58,017 -87,703 -423,651
9,065 138,251 9,126 138,110 9,199 145,451 9,738 145,295 8,787 149,032 8,787 150,131 316,737
-2,326 0.0 -1,882 -1,882 -1,882 -1,882 -49,978 -51,603 1.5 976 1,321 -1,007 1,291
-157,070 -69,547 -470,878 -203,502 22 36,555 -9,886 -25,615
-140,655 -97,760 -58,223 316,381 -110,045 -655,969 -301,792 -214,900 -11,981 -192,447 -77,492 -180,348 -462,268
1,671 -29,692 169,441 347,212 54,003 -364,889 -109,013 -35,105 331,478 -26,549 -59,883 -134,072 110,974
128,862 69,327 214,262 16,813 188,511 327,105 129,435 140,355 325,403 150,879 10,135 73,812 560,229

LTM = last twelve months (sum of the four most recent quarters).

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?